Qiagen N.V. $QGEN Stock Holdings Lifted by Governors Lane LP

Governors Lane LP grew its position in Qiagen N.V. (NYSE:QGEN) by 24.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 68,720 shares of the company’s stock after purchasing an additional 13,698 shares during the period. Governors Lane LP’s holdings in Qiagen were worth $2,687,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after buying an additional 906,589 shares during the last quarter. Deutsche Bank AG grew its position in Qiagen by 9.7% in the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after acquiring an additional 697,342 shares in the last quarter. Amundi increased its stake in shares of Qiagen by 12.4% during the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock worth $190,498,000 after purchasing an additional 524,959 shares during the last quarter. Boston Partners bought a new position in shares of Qiagen during the 3rd quarter valued at $179,450,000. Finally, Norges Bank acquired a new stake in shares of Qiagen in the 4th quarter valued at $166,500,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Performance

NYSE QGEN opened at $42.37 on Wednesday. The company’s fifty day moving average is $42.05 and its two-hundred day moving average is $40.25. Qiagen N.V. has a 52-week low of $32.53 and a 52-week high of $57.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The firm has a market capitalization of $8.73 billion, a price-to-earnings ratio of 21.71, a P/E/G ratio of 4.33 and a beta of 0.63.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The business had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the business earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts forecast that Qiagen N.V. will post 2.43 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on QGEN. JPMorgan Chase & Co. raised their target price on Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Weiss Ratings upgraded Qiagen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, August 17th. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price objective on shares of Qiagen in a research note on Thursday, August 6th. Citigroup reiterated a “neutral” rating and issued a $45.00 target price (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Finally, Barclays set a $40.00 price target on shares of Qiagen and gave the company an “equal weight” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $43.93.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.